Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Consultation record

Submissions accepted — page 21

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

681 documents · page 21 of 23

Table 1. Submissions with this disposition, on this page.

ReferenceConsultationRespondentPoint raised
DRAFT-ORAL-VS-INJE/002Draft synthesis: Oral compared with injectable presentations of…Dr Wolfram Kaltenbach-MensahThe same concept is given three different names in one document
DRAFT-ORAL-VS-INJE/012Draft synthesis: Oral compared with injectable presentations of…Dr Anselm Ashworth-DanquahRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-ORAL-VS-INJE/004Draft synthesis: Oral compared with injectable presentations of…Dr Amara QuaresmaIntention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-ORAL-VS-INJE/006Draft synthesis: Oral compared with injectable presentations of…Dr Liesbeth QuennevilleThe conclusion is stated more strongly than the certainty rating supports
DRAFT-ORAL-VS-INJE/001Draft synthesis: Oral compared with injectable presentations of…Quentin Gwynne-SarpongEfficacy outcomes are rated for certainty and harms are not
DRAFT-RENAL-OUTCOM/008Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Mordecai Glendinning-UcheOverlapping primary studies across included reviews are counted more than once
DRAFT-RENAL-OUTCOM/006Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Anselm Thorsby-NakamuraA single-trial result is presented in the visual form of a pooled estimate
DRAFT-RENAL-OUTCOM/003Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Séverin Oppenheimer-AdeRegistered trials that never reported are not counted anywhere in the review
DRAFT-RENAL-OUTCOM/001Draft synthesis: Kidney outcomes with incretin receptor agonists in…Vasilisa Sandringham-AduThe conclusion is stated more strongly than the certainty rating supports
DRAFT-RENAL-OUTCOM/007Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Vittoria YlönenResults at materially different follow-up durations are pooled
DRAFT-RENAL-OUTCOM/009Draft synthesis: Kidney outcomes with incretin receptor agonists in…Dr Abimbola Sotomayor-EkwuemeDoses differing several-fold are pooled without examining dose-response
DRAFT-HFPEF-INCRET/004Draft synthesis: Incretin receptor agonists in heart failure with…Dr Oswin YorkstoneThe conclusion is stated more strongly than the certainty rating supports
DRAFT-SLEEP-APNOEA/005Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Jacinta Grünbaum-SowandeThe search strategy as published cannot be re-run
DRAFT-SLEEP-APNOEA/001Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Sigrún LavrentievResults at materially different follow-up durations are pooled
DRAFT-SLEEP-APNOEA/015Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Anselm Ashworth-DanquahOverlapping primary studies across included reviews are counted more than once
DRAFT-SLEEP-APNOEA/010Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Ursina Ellsworth-VanceAbsence of evidence is presented in a form a reader will take as negative evidence
DRAFT-SLEEP-APNOEA/009Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Piotr HollingworthStudies using different outcome definitions are pooled into one estimate
DRAFT-SLEEP-APNOEA/003Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Yehudit YorkstoneThe review does not say when it will be updated or what would trigger an update
DRAFT-SLEEP-APNOEA/004Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Melisande Thorsby-NakamuraA single-trial result is presented in the visual form of a pooled estimate
DRAFT-SLEEP-APNOEA/016Draft synthesis: Weight-reducing agents for obstructive sleep apnoeaDr Bertrand Steenkamp-FerreiraIntention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-COA-COMPLETE/007Draft synthesis: Completeness of certificates of analysis in the…Dr Jerome PetrossianA funnel plot is presented for a set too small to interpret it
DRAFT-COA-COMPLETE/003Draft synthesis: Completeness of certificates of analysis in the…Dr Hortensia Larsson-EkwuemeAnalytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-COA-COMPLETE/002Draft synthesis: Completeness of certificates of analysis in the…Dr Quentin Whitmarsh-ObiRisk-of-bias judgements are reported as an overall rating without the domains
DRAFT-COA-COMPLETE/001Draft synthesis: Completeness of certificates of analysis in the…Dr Delphine TrelawneyThe review does not say when it will be updated or what would trigger an update
DRAFT-COUNTERION-C/002Draft synthesis: Counter-ion content and its effect on delivered…Dr Xenia UttridgeAn indirect comparison is presented without an assessment of transitivity
DRAFT-COUNTERION-C/015Draft synthesis: Counter-ion content and its effect on delivered…Dr Yehudit YorkstoneA funnel plot is presented for a set too small to interpret it
DRAFT-COUNTERION-C/016Draft synthesis: Counter-ion content and its effect on delivered…Dr Melisande Thorsby-Nakamura industryTwo factual descriptions of the sponsor's programme are inaccurate
DRAFT-COUNTERION-C/014Draft synthesis: Counter-ion content and its effect on delivered…Dr Katarzyna YorkstoneThe review does not say when it will be updated or what would trigger an update
DRAFT-COUNTERION-C/004Draft synthesis: Counter-ion content and its effect on delivered…Kolawole Jankowiak-OseiAnalytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-COUNTERION-C/006Draft synthesis: Counter-ion content and its effect on delivered…Rosalind PetrossianThe review does not say when it will be updated or what would trigger an update

page 21 of 23

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.